Obefazimod
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Obefazimod
- Molecular weight
- 338.72
- Structure (SMILES)
- FC(F)(F)Oc1ccc(Nc2ccc3cccc(Cl)c3n2)cc1
- abx 464
- Abx 464
- Abx-464
- ABX-464
- abx464
- Abx464
- ABX464
- ABX464 100 mg
- ABX464 100mg
- ABX464 150mg
- ABX464 25 mg
- ABX464 50 mg
- ABX464 50mg
- obefazimod
- Obefazimod
- obefazimod [INN]
- OBEFAZIMOD [USAN]
- Obefazimod [WHO-DD]
- Obefazimod 50 mg Capsule
- obefazimod inn
- obefazimod usan
- obefazimod who dd
- spl 464
- SPL-464
- CAS registry numbers
- 1258453-75-6
- ChEMBL ID
- CHEMBL4297344
- InChIKey
- OZOGDCZJYVSUBR-UHFFFAOYSA-N
- PubChem compound IDs
- 49846599
- FDA ingredient codes (UNII)
- 26RU378B9V
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- obefazimod
- Type
- Synthetic organic
- Drug name stem
- -imod
- Mechanism
- Cap binding complex modulator
- Action type
- MODULATOR
- Target
- Cap binding complex
- Protein identifier
- P52298
- Mechanism
- Cap binding complex modulator
- Action type
- MODULATOR
- Target
- Cap binding complex
- Protein identifier
- Q09161
Open Targets mechanisms
- Mechanism
- Cap binding complex modulator
- Action type
- MODULATOR
- Target
- Cap binding complex
- Condition
- Crohn Disease
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000384
- Subject identifier
- D003424
- Condition
- Arthritis, Rheumatoid
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000685
- Subject identifier
- D001172
- Condition
- Colitis, Ulcerative
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000729
- Subject identifier
- D003093
- Condition
- HIV Infections
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000764
- Subject identifier
- D015658
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0100096
- Subject identifier
- D045169
- Condition identifier
- EFO_0000180
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000384
- Condition identifier
- EFO_0000685
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000729
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000764
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0001208
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005011
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005101
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005109
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0008383
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0100096
- Condition identifier
- MP_0001845
- Highest recorded phase
- 2
- NCT02452242
- NCT02735863
- NCT02990325
- NCT03093259
- NCT03368118
- NCT03760003
- NCT04023396
- NCT05177835
- NCT05507203
- NCT05507216
- NCT05535946
- NCT03813199
- NCT04049448
- NCT03905109
- NCT06456593
- NCT04393038
- Hydrogen bond acceptors
- 3
- Hydrogen bond donors
- 1
- Polar surface area
- 34.15
- Calculated partition coefficient (ALogP)
- 5.53
- Calculated partition coefficient (XLogP)
- 5.9
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 3
- Heavy atoms
- 23
- Molecular formula
- C16H10ClF3N2O
- Monoisotopic mass
- 338.0433751
- Natural product
- No
- Recorded assays
- 24
- Active assays
- 1
Active assay types
- Confirmatory
Related records
Trials (21)
- A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seropositive Adults
- ABTECT - Maintenance
- ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1
- ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2
- ABX464 First in Man Study
- ABX464 in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor Treatment
- ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis
- ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19
- Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
- Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
- Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis
- Evaluation of the Potential CYP1A2-mediated Drug Drug Interaction Safety, and Tolerability of ABX464
- Food Effect on Pharmacokinetic Parameters of ABX464
- Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis
- Phase 2b/3 Study of ABX464 in Moderate to Severe Active Crohn's Disease Patients
- Safety and Pharmacokinetics Study in Healthy Japanese Volunteers
- Safety, PK and PD Study of ABX464 in Untreated HIV Patients
- Study Evaluating the Long-term Safety and Efficacy of ABX464 in Active Ulcerative Colitis
- Study Evaluating the Long-Term Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid Arthritis
- Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis
In development for (5)
- COVID-19 Phase 2
- Crohn disease Phase 2
- HIV infectious disease Phase 2
- Rheumatoid arthritis Phase 2
- Ulcerative colitis Phase 3